V118C Vaccine for Pneumococcal Infections
What You Need to Know Before You Apply
What is the purpose of this trial?
Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria.
This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.
Who Is on the Research Team?
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Are You a Good Fit for This Trial?
This trial is for toddlers and infants who are about 2 months old, born at full term (37 weeks or more), and have already received 3 doses of the PCV20 vaccine. They should be between 12 to 15 months old to participate.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- V118C
Trial Overview
The study is testing a new pneumococcal vaccine called V118C in children. It aims to determine the safety and tolerance of this vaccine compared to PCV20, which is an existing pneumococcal vaccine.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Active Control
Participants will receive a single 0.5 mL IM injection of V118C administered at 2,4,6, and 12 months of age.
Participants will receive a single 0.5 mL intramuscular (IM) injection of V118C administered at 12 to 15 months of age.
Participants will receive a single 0.5 mL IM injection of PCV20 administered at 12 to 15 months of age.
Participants will receive a single 0.5 mL IM injection of PCV20 administered at 2,4,6, and 12 months of age.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.